Abstract:Background: Bronchial asthma (BA) is a heterogeneous disease characterized primarily by chronic airway inflammation and airway hyperresponsiveness (AHR). Objectives: This was a retrospective study aimed at exploring the clinical efficacy of spleen aminopeptide (SA) combined with budesonide (BUD) and levosalbutamol hydrochloride (LEV) as a therapy for pediatric BA, and to observe its effects on inflammatory markers and immune function. Methods: From June 2022 to June 2023, eighty individuals diagnosed with BA were divided into two groups: A control group and an observation group, based on different therapeutic methods. The control group received inhalation therapy with nebulized BUD and LEV, while the observation group received the same inhalation therapy as the control group, along with SA oral lyophilized powder (SAOLP) treatment. A comparative analysis was conducted between the two groups, evaluating clinical efficacy, changes in inflammatory markers and immunological parameters, and adverse drug reactions (ADRs). Results: Upon treatment completion, the observation group exhibited an overall response rate (ORR) of 95.00%, whereas the control group showed an ORR of 80.00% (P < 0.05). Additionally, the observation group had a significantly shorter length of hospital stay (LoHS) and a more rapid improvement in symptoms compared to the control group (both P < 0.05). Following treatment, both groups demonstrated significant decreases in interleukin‐2 (IL‐2), interleukin‐4 (IL‐4), interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), and tumor necrosis factor‐α (TNF‐α) levels (all P < 0.05). However, these reductions were more pronounced in the observation group than in the control group (all P < 0.05). Similarly, after treatment, both groups showed significant increases in T cell subsets CD3+ and CD4+, the CD4+/CD8+ ratio, and levels of immunoglobulin M (IgM), immunoglobulin A (IgA), and immunoglobulin G (IgG) (all P < 0.05), with these changes being more evident in the observation group than in the control group (all P < 0.05). Both groups experienced adverse reactions during the treatment, with an overall adverse reaction rate (OADRR) of 7.50% in the observation group and 10.00% in the control group (χ2 = 0.157, P = 0.692). Conclusions: The combined therapy using SA, BUD, and LEV can significantly improve immune function and reduce inflammatory markers, thereby achieving satisfactory efficacy in treating pediatric BA with a clinically safe profile.

The Effectiveness of Budesonide Nebulized Inhalation Combined with Systematic Nursing Intervention in the Treatment of Acute Asthma Attacks in Children

Clinical study on inhalation of budesonid with nebulizer in the treatment of children with asthma

Budesonide in Combination with Salbutamol in the Treatment of 61 Cases of Childhood Bronchial Asthma During Acute Episodes

Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma

Meta-analysis of the efficacy of budesonide and ambroxol hydrochloride inhalation in children with pneumonia and their effects on inflammatory response

A Three-Month Non-Interventional Study of Asthma Treatment with Budesonide/Formoterol

Treatment of Pediatric Mild Persistent Asthma with Low-Dose Budesonide Inhalation Suspension Vs.montelukast in China

Effects of budesonide combined with salbutamol on pulmonary function and peripheral blood eosinophiles and IgE in patients with acute attack of bronchial asthma

Effects of Budesonide Plus Vitamin AD on Children with Bronchial Asthma and the Effect on Serum IgE and C-reactive Protein

Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis

A Multi-Center Trial for the Efficacy of Nebulized Budesonide Inhalation in Infants and Young Children with Asthma Exacerbations

Inhaled Budesonide vis-à-vis Inhaled Mometasone in Chinese Children with Mild Persistent Asthma: A Single-Center, Retrospective Study

The Efficacy of Budesonide-formoterol in Patients with Acute Attacks of Mild-to-moderate Bronchial Asthma: An Observational Study

Inhaled budesonide versus oral prednisolone in the treatment of acute exacerbation of moderate bronchial asthma: an open label randomized clinical trial

Clinical Efficacy of Spleen Aminopeptide Combined with Budesonide and Levosalbutamol Hydrochloride, and Its Effects on Inflammatory Markers and Immune Function in Pediatric Bronchial Asthma

Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils

Efficacy of budesonide/formoterol inhalation powder in treating viral pneumonia in children

Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma

The efficacy of nebulized budesonide and ambroxol hydrochloride in treating pediatric community-acquired pneumonia and their impact on clinical characteristics and inflammatory markers

Effect of comprehensive nursing intervention on the efficacy of spleen aminopeptide combined with aerosol inhalation in the treatment of pediatric pneumonia

Comparison of the Effects of Beclomethasone Dipropionate and Budesonide in the Treatment of Children with Mild, Persistent Asthma